Raab & Moskowitz Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $845K | Hold |
1,701
| – | – | 0.17% | 105 |
|
|
2026
Q1 | $760K | Hold |
1,701
| – | – | 0.17% | 105 |
|
|
2025
Q4 | $771K | Hold |
1,701
| – | – | 0.17% | 107 |
|
|
2025
Q3 | $666K | Hold |
1,701
| – | – | 0.15% | 113 |
|
|
2025
Q2 | $757K | Hold |
1,701
| – | – | 0.18% | 102 |
|
|
2025
Q1 | $825K | Hold |
1,701
| – | – | 0.21% | 94 |
|
|
2024
Q4 | $685K | Sell |
1,701
-48
| -3% | -$22.3K | 0.17% | 103 |
|
|
2024
Q3 | $813K | Sell |
1,749
-37
| -2% | -$17.8K | 0.21% | 93 |
|
|
2024
Q2 | $837K | Buy |
1,786
+48
| +3% | +$20.8K | 0.23% | 87 |
|
|
2024
Q1 | $727K | Hold |
1,738
| – | – | 0.2% | 95 |
|
|
2023
Q4 | $707K | Sell |
1,738
-27
| -2% | -$9.97K | 0.22% | 93 |
|
|
2023
Q3 | $614K | Hold |
1,765
| – | – | 0.22% | 95 |
|
|
2023
Q2 | $621K | Hold |
1,765
| – | – | 0.21% | 94 |
|
|
2023
Q1 | $556K | Sell |
1,765
-58
| -3% | -$17.4K | 0.2% | 98 |
|
|
2022
Q4 | $526K | Buy |
1,823
+125
| +7% | +$38.1K | 0.2% | 101 |
|
|
2022
Q3 | $491K | Sell |
1,698
-5
| -0.3% | -$1.44K | 0.21% | 101 |
|
|
2022
Q2 | $479K | Hold |
1,703
| – | – | 0.19% | 111 |
|
|
2022
Q1 | $444K | Buy |
1,703
+50
| +3% | +$11.9K | 0.15% | 118 |
|
|
2021
Q4 | $363K | Hold |
1,653
| – | – | 0.12% | 129 |
|
|
2021
Q3 | $300K | Hold |
1,653
| – | – | 0.11% | 137 |
|
|
2021
Q2 | $333K | Hold |
1,653
| – | – | 0.12% | 130 |
|
|
2021
Q1 | $355K | Buy |
1,653
+15
| +0.9% | +$3.29K | 0.14% | 115 |
|
|
2020
Q4 | $387K | Sell |
1,638
-6
| -0.4% | -$1.38K | 0.16% | 111 |
|
|
2020
Q3 | $447K | Buy |
1,644
+4
| +0.2% | +$1.1K | 0.21% | 99 |
|
|
2020
Q2 | $476K | Sell |
1,640
-28
| -2% | -$7.59K | 0.23% | 95 |
|
|
2020
Q1 | $396K | Hold |
1,668
| – | – | 0.22% | 98 |
|
|
2019
Q4 | $365K | Hold |
1,668
| – | – | 0.14% | 122 |
|
|
2019
Q3 | $282K | Hold |
1,668
| – | – | 0.12% | 135 |
|
|
2019
Q2 | $305K | Hold |
1,668
| – | – | 0.14% | 132 |
|
|
2019
Q1 | $306K | Hold |
1,668
| – | – | 0.14% | 130 |
|
|
2018
Q4 | $276K | Hold |
1,668
| – | – | 0.14% | 130 |
|
|
2018
Q3 | $321K | Hold |
1,668
| – | – | 0.13% | 129 |
|
|
2018
Q2 | $283K | Hold |
1,668
| – | – | 0.14% | 129 |
|
|
2018
Q1 | $271K | Buy |
+1,668
| New | +$272K | 0.13% | 130 |
|
Other funds holding VRTX
Raab & Moskowitz Asset Management's VRTX Position: Q2 2026 in Review
Raab & Moskowitz Asset Management held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 1,701 shares worth $845K. The position accounts for 0.17% of the portfolio, ranked #105.
Raab & Moskowitz Asset Management first reported a position in VRTX in Q1 2018 and has held it in 34 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Raab & Moskowitz Asset Management held 1,701 shares of Vertex Pharmaceuticals worth $845K as of Q2 2026.
- Raab & Moskowitz Asset Management left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
- Vertex Pharmaceuticals made up 0.17% of Raab & Moskowitz Asset Management's portfolio in Q2 2026, its #105 holding.
- Raab & Moskowitz Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2018 and has held it in 34 quarters since.
- 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Raab & Moskowitz Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.